STOP-SCD-VTE: STudy of anticoagulation Outcomes and Practice patterns for patients with Sickle Cell Disease and Venous ThromboEmbolism - Project Summary/Abstract Sickle cell disease (SCD), a genetic hemoglobinopathy affecting 100,000 individuals in the US, is a clinically heterogeneous diffuse vasculopathy, with accelerated mortality. Venous thromboembolism, including deep venous thrombosis and pulmonary embolism, is common, highly recurrent and increases SCD mortality risk nearly three-fold. While the elevated risk of recurrent VTE led the American Society of Hematology (ASH) Clinical Guidelines committee to recommend indefinite anticoagulation after a first-time VTE in adults with SCD, the effects of this strategy on clinical outcomes is unknown. Additionally, there are limited data to support which of the two most commonly prescribed classes of oral anticoagulants, vitamin K antagonists (i.e., warfarin) or direct oral anticoagulants (i.e., apixaban, rivaroxaban) has the greatest efficacy with the lowest risk of hemorrhage. We plan to use three real world registries, one SCD non-specific (TriNetX) and two SCD specific (Globin Regional Data and Discovery [GRNDaD] and the ASH Research Collaborative [ASH RC] Datahub) to explore our hypotheses that: 1) Idiosyncratic hospital-practice pattern variation in the use of long- term anticoagulation for a first-time VTE in patients living with SCD occurs and drives treatment disparities; and 2) Implementation of the conditional ASH clinical guideline for longer-term AC and, possibly, use of direct oral anticoagulants reduce the frequency of VTE recurrence, subsequent vasoocclusive events, right-sided cardiac disease/pulmonary hypertension and mortality in adults with SCD. To investigate these hypotheses, we have formed a multi-disciplinary research team with expertise in health services and clinical outcomes research, pulmonology, hematology and advanced statistical methods including causal mediation analysis and target trial emulation using real-world data. This multi-PI proposal is led by Drs. Elizabeth Klings, an expert in the pulmonary vascular complications of sickle cell disease, and Allan Walkey, a clinical epidemiologist and health services researcher new to sickle cell disease research with expertise in leveraging practice pattern variation to identify and compare care practices with the goal of improving health of patients. We seek to understand: 1) Factors that influence the type and duration of anticoagulation for treatment prescribed to patients with SCD and a first time VTE; 2) Differences in 3 year clinical outcomes for patients with SCD and a first-time VTE treated with warfarin compared with direct oral anticoagulants; and 3) Differences in 3-5 year clinical outcomes for patients with SCD and a first-time VTE treated with short- vs long-term anticoagulation. By completion of this proposal, we will understand current anticoagulation practices for VTE in SCD, and risks and benefits of common treatment strategies for patients with SCD who experience a VTE, in order to inform future implementation strategies designed to improve the lives of patients living with sickle cell disease.